Search Results - "Abdel-Razeq H"

533P Real-world evidence on safety and effectiveness study of ribociclib plus hormonal therapy in HR+/HER2– advanced breast cancer in the middle east: Interim results from the REALEESA study.

Authors: Abdel-Razeq, H. Alsayed, A. Dawoud, E. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS426-S426. 1p.

A randomized study of multi-day infusion of autologous peripheral blood progenitor cells.

Authors: Abdel-Razeq, H Pohlman, B Andresen, S et al.

Source: Bone Marrow Transplantation. 2/1/98, Vol. 21 Issue 3, p221. 3p. 4 Charts.

Bone health in breast cancer survivors.

Authors: Abdel-Razeq H Awidi A

Source: Journal of Cancer Research & Therapeutics. Jul-Sep2011, Vol. 7 Issue 3, p256-263. 8p.

500P The impact of COVID-19 on the management and outcome of oncology patients: The results of the Middle East and North African (MENA) COVID-19 and Cancer Registry (MCCR).

Authors: Jazieh, A.R. Abdel-Razeq, H. Köksoy, E.B. et al.

Source: Annals of Oncology. 2022 Supplement 7, Vol. 33, pS771-S771. 1p.

328PRibociclib (RIBO) + letrozole (LET) in premenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) with no prior endocrine therapy (ET) for ABC: Preliminary subgroup results from the phase IIIb CompLEEment-1 trial

Authors: Abdel-Razeq, H Cottu, P H Ring, A et al.

Source: Annals of Oncology. 2018 Supplement, Vol. 29, pN.PAG-N.PAG. 1p.

Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial.

Authors: Alsaleh, K. Al Zahwahry, H. Bounedjar, A. et al.

Source: Journal of Cancer Research & Clinical Oncology. Aug2023, Vol. 149 Issue 9, p6171-6179. 9p.

2579P Development of a patient-reported outcome measure for individuals at risk for hereditary cancer: Phase I - IIIa of the EORTC QLQ-HCR30.

Authors: Engele, V.I. Vasiliou, V. Wheelwright, S. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS1384-S1385. 2p.

393P Baseline stage retains prognostic value after pathologic complete response in breast cancer: A SEER-based analysis.

Authors: Tamimi, F.T. Sharf, B.S. El Khatib, O. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS365-S366. 2p.

3191eP Development of an EORTC strategy to measure health-related quality of life in cancer patients receiving immune checkpoint inhibitors: Phase I and II.

Authors: Fox, L. Egeler, M. Singer, S. et al.

Source: Annals of Oncology. 2025 Supplement 2, Vol. 36, pS695-S695. 1p.

PO-1298 Clinical predictors of dosimetric precedence for (DIBH) radiation therapy for breast cancer.

Authors: Abdelqader, S. Abuhijli, F. Abuhijlih, R. et al.

Source: Radiotherapy & Oncology. 2023 Supplement 1, Vol. 182, pS1040-S1041. 2p.

57MO First-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs combination chemotherapy (combo CT) in HR+/HER2− advanced breast cancer (ABC): A post hoc analysis of Asian and non-Asian patients (pts) from the phase II RIGHT choice trial.

Authors: Yap, Y-S. Im, S-A. Lu, Y-S. et al.

Source: Annals of Oncology. 2023 Supplement 4, Vol. 34, pS1488-S1488. 1p.

1449P Aggressiveness of cancer care at end of life in patients with metastatic breast cancer: A regional perspective.

Authors: Abunasser, M.K. Saadeh, S.S. Salama, O. et al.

Source: Annals of Oncology. 2021 Supplement 5, Vol. 32, pS1078-S1079. 2p.

Precise radiation, better airway preservation: vocal cord-only image-guided intensity-modulated radiation therapy for early-stage glottic cancer.

Authors: Mohamad I Alotain I Abu Taha S et al.

Source: Frontiers in oncology [Front Oncol] 2026 May 20; Vol. 16, pp. 1847970. Date of Electronic Publication: 2026 May 20 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Comprehensive genomic analysis of non-BRCA familial breast cancer in an Arab population.

Authors: Ullah E Abdel-Razeq H Bentebbal S et al.

Source: NPJ breast cancer [NPJ Breast Cancer] 2026 Mar 19; Vol. 12 (1). Date of Electronic Publication: 2026 Mar 19.

Publication Type: Journal Article

Journal Info: Publisher: Breast Cancer Research Foundation Country of Publication: United States NLM ID: 101674891 Publication Model: Electronic Cited Medium: Print ISSN: 2374-4677 (Print) Linking ISSN: 23744677 NLM ISO Abbreviation: NPJ Breast Cancer Subsets: PubMed not MEDLINE

Prostatectomy versus definitive radiation for localized prostate cancer: revisiting the debate at a tertiary cancer center.

Authors: Abu-Hijlih R Alzibdeh A Abaza H et al.

Source: Frontiers in oncology [Front Oncol] 2026 Mar 02; Vol. 16, pp. 1756635. Date of Electronic Publication: 2026 Mar 02 (Print Publication: 2026).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE

Qualitative insights into employment challenges faced by cancer patients and caregivers in a limited-resource country.

Authors: Al-Omari A Mansour R Altalla' B et al.

Source: Frontiers in psychology [Front Psychol] 2026 Jan 13; Vol. 16, pp. 1714566. Date of Electronic Publication: 2026 Jan 13 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: Frontiers Research Foundation Country of Publication: Switzerland NLM ID: 101550902 Publication Model: eCollection Cited Medium: Print ISSN: 1664-1078 (Print) Linking ISSN: 16641078 NLM ISO Abbreviation: Front Psychol Subsets: PubMed not MEDLINE

Dose adjusted EPOCH-R is superior to RCHOP in frontline treatment of mediastinal large B cell lymphoma.

Authors: Ma'koseh M Yaseen A Abed NA et al.

Source: Hematology (Amsterdam, Netherlands) [Hematology] 2025 Dec; Vol. 30 (1), pp. 2515337. Date of Electronic Publication: 2025 Jun 18.

Publication Type: Journal Article

Journal Info: Publisher: Taylor & Francis Country of Publication: England NLM ID: 9708388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1607-8454 (Electronic) Linking ISSN: 10245332 NLM ISO Abbreviation: Hematology Subsets: MEDLINE

Evolving First-Line Endocrine Therapy in HR+/HER2- Metastatic Breast Cancer: CDK4/6 Inhibition, Biomarker-Guided Strategies and Emerging Therapeutic Paradigms.

Authors: Abdel-Razeq H Sharaf B

Source: Current oncology (Toronto, Ont.) [Curr Oncol] 2026 Jul 14; Vol. 33 (7). Date of Electronic Publication: 2026 Jul 14.

Publication Type: Journal Article; Review

Journal Info: Publisher: MDPI Country of Publication: Switzerland NLM ID: 9502503 Publication Model: Electronic Cited Medium: Internet ISSN: 1718-7729 (Electronic) Linking ISSN: 11980052 NLM ISO Abbreviation: Curr Oncol Subsets: MEDLINE

Precision Endocrine-Based Combinations After CDK4/6 Inhibitor Progression in HR-Positive Metastatic Breast Cancer.

Authors: Abdel-Razeq H; Section of Hematology and Medical Oncology, Department of Internal Medicine, King Hussein Cancer Center, Amman, 11941, Jordan.; School of Medicine, the University of Jordan, Amman, 11941, Jordan.

Source: Drug design, development and therapy [Drug Des Devel Ther] 2026 Jul 09; Vol. 20, pp. 611371. Date of Electronic Publication: 2026 Jul 09 (Print Publication: 2026).

Publication Type: Journal Article; Review

Journal Info: Publisher: Dove Press Limited Country of Publication: New Zealand NLM ID: 101475745 Publication Model: eCollection Cited Medium: Internet ISSN: 1177-8881 (Electronic) Linking ISSN: 11778881 NLM ISO Abbreviation: Drug Des Devel Ther Subsets: MEDLINE

Minimally invasive circulating MicroRNA signatures for breast cancer detection and neoadjuvant therapy response prediction in a multicenter MENA cohort.

Authors: Vishnubalaji R Abdel-Razeq H Gehani SA et al.

Source: Journal of translational medicine [J Transl Med] 2026 Jul 08. Date of Electronic Publication: 2026 Jul 08.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 101190741 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1479-5876 (Electronic) Linking ISSN: 14795876 NLM ISO Abbreviation: J Transl Med Subsets: MEDLINE